MAP2K7 and neoplasm: Within this context, especially MEK inhibitors (MEKi) have received a substantial amount of scientific attention due to their preclinically observed potential to significantly alter the tumor-associated pro-tumorigenic immune response towards an anti-tumorigenic inflammatory response (10, 13).